The global bleeding disorders treatment market is projected to reach USD 15.09 billion by 2021 from USD 10.33 billion in 2016, at a CAGR of 7.9% from 2016 to 2021.
The increasing acceptance for prophylaxis treatment among all age groups, rising volume of diagnosed patients, and increasing R&D investments for the development of hemophilia products are driving the global market for bleeding disorders treatment. On the other hand, high costs for bleeding disorder treatment products is a major factor expected to restrain the growth of this market during the forecast period.
The global bleeding disorders treatment market is broadly classified by type and drug class. The hemophilia A segment is projected to register a healthy CAGR during the forecast period. The large number of patients suffering from hemophilia A and rising R&D investment for hemophilia products
The recombinant coagulation factor concentrates segment is expected to witness the highest growth rate in the bleeding disorders treatment market. This growth is attributed to rising R&D activities and increasing focus of pharmaceutical companies on recombinant products resulting in launch of new products.
Geographically, the bleeding disorders treatment market is dominated by North America, followed by Europe. The increasing acceptance of prophylaxis treatment across all age groups is a key factor driving the North American bleeding disorder treatment market.
Baxalta (Now Shire)
Novo Nordisk A/S
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Market Dynamics
5 Global Bleeding Disorders Treatment Market, By Type
6 Global Bleeding Disorders Treatment Market, By Drug Class
7 Global Bleeding Disorders Treatment Market, By Geography